Free Goods Programme

We aim to help solve the toughest imbalances in access to medicine and to positively impact people’s lives around the world.

SUMMARY

At Cycle we are committed to developing safe and effective therapies and making them available to as many patients as possible.

Girl in pink and blue garment

We’re committed to helping rare disease patients irrespective of their ability to pay for treatment. This is written into the constitutional documents of our company, and we’ve been running a Free Goods Programme since 2018.

A Free Goods Programme is a compliant way for medicines that are not approved in their country of intended use to be made available for patients who either have no alternative treatment option or have exhausted all other treatment options available in their country of residence.

Our Free Goods Programme is currently available to patients with Hereditary Tyrosinemia Type 1 (HT-1) and Alkaptonuria (AKU) who live in countries where it is unlikely that they will have the means to pay for rare disease medication, including Argentina, Bangladesh, Brazil, Chile, Colombia, Dominican Republic, India, Jordan, Mexico, Nigeria, Pakistan, Peru, Sudan, Tunisia and Turkey.

HT-1 and AKU are both ultra-rare diseases, and they are both diseases that patients have for life. They can be treated with nitisinone, in combination with dietary restriction of tyrosine and phenylalanine.

We aim to provide nitisinone to 100 patients on the Free Goods Programme and are committed to providing it to these patients for free, for the duration of their life.

How to access

If you are a Healthcare Professional (HCP) who believes that access to nitisinone would be suitable for your patient, you should contact Cycle via medinfo@cyclepharma.com or visit www.inceptua.com to make the request on behalf of your patient. These requests should not include information that identifies the patient.

We can’t deal with patients directly, so if you are a patient, please ask your HCP to contact us.

Conditions

To be able to make a request, you must be appropriately licensed and qualified to administer the product to the patient in the relevant territory. To be admitted to the programme, the patient must fulfil the below criteria:

  • The patient must live in or be primarily treated in a country served by the Cycle Free Goods Programme.
  • The patient must be assessed by their HCP as suffering from a disease that could be treated by nitisinone, and the HCP must judge that the benefit to the patient outweighs the potential risk of taking nitisinone.
  • The programme must be open to new patients at the time of application.
  • Supply to the patient under the programme must not break any local laws or regulations.

Where patients satisfy the requirements for demonstrating that there is a clinical need for nitisinone, Cycle will add patients to the programme on a first come first served basis.

Inceptua logo

Making it possible

We have partnered with Inceptua to provide our Free Goods Programme.

Find out more at www.inceptua.com

For Cycle Pharmaceuticals
Medical Information

TELEPHONE:
+1 800 841 0898
E-MAIL:
OUR MANAGEMENT TEAM
TECHNOLOGY PARTNERSHIPS